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Chlamydia trachomatis causes the most prevalent bacterial Sexual Transmitted Infection. In
pregnant women, untreated chlamydial infections are associated with abortions, premature
rupture of membranes, postpartum endometritis, low birth weight and transmission to the
newborn. In Córdoba, Argentina, there is little knowledge about the prevalence of Chla-
mydia trachomatis in women in their third trimester of pregnancy, so, the aim of this study
was to evaluate Chlamydia trachomatis prevalence and genotypes present in Cordovan
pregnant women with different age and socioeconomic status.
Methods and findings
Design: prospective study.
Settings: Women population from Cordoba city, Argentina.
Population: Pregnant women having 35 to 37 weeks of gestation.
Methods: Five hundred and nine cervical swabs were collected. Each sample was sub-
jected to DNA extraction and PCR for Chlamydia trachomatis using primers NRO/NLO and
CTP1/CTP2. Positives samples were sequenced to determine genotype. Main outcome
measures: Demographic data of the patients were collected to detect a population at risk for
this infection.
Results
A prevalence of 6.9% (35/509) for Chlamydia trachomatis infection was detected, with 32/
295 and 3/214 from pregnant women with low or better economic resources respectively
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(p = 0,0001). Results showed a significantly increased rate of 11.6% (30/258) in women
under 25 years compared with 2% (5/251) in patients over that age (p = 0,00003). Genotype
E was the most prevalent.
Conclusions
With these results, we can say that pregnant women under 25 years old and low economic
resources are one of the populations in which the screening programs of Chlamydia tracho-
matis should focus.
Introduction
Chlamydia trachomatis (C. trachomatis) is an obligate intracellular Gram negative bacterium
causing the most prevalent bacterial Sexual Transmitted Infection (STI) throughout the world.
The World Health Organization (WHO) estimated that annually some 357 million people get
one STI include: chlamydia, gonorrhea, syphilis or trichomoniasis [1]. According to ompA
gene molecular differences, C. trachomatis could be divided into different genotypes that are
responsible for various diseases: genotypes A, B, Ba and C causing trachoma; genotypes D, Da,
E, F, G, H, I, Ia, J and K responsible for urogenital infections in adults and respiratory and con-
junctival infections in neonates and genotypes L1, L2, L2a and L3 causing Lymphogranuloma
venereum [2, 3]. The most important characteristic of C. trachomatis is the ability to produce
acute complications and long-term sequelae in upper genital tract, thus affecting the reproduc-
tive health.
In women, C. trachomatis infection presents asymptomatically in 70–75% of cases. Eng and
Butler found that 30–40% of sexually active teenagers were infected [4] and up to 40% of them
may develop pelvic inflammatory disease (PID) if not received the specific antimicrobial treat-
ment [5]. C. trachomatis mainly affects women and adolescents younger than 20 years old. It
has been postulated the immature cervix is more susceptible to C. trachomatis infection, so
younger women are more prone to infection than older women [6, 7].
Infection prevalence reported in pregnant women is 3.5% in USA [8], 12.1% in the UK [9],
6.4% in Australia [10], 11% in Brazil and 10% in Perú [11, 12]. Untreated chlamydial infection
in pregnant women is associated with miscarriage, postpartum endometritis, premature rup-
ture of membranes, low birth weight and transmission to the newborn [13]. Some studies sug-
gest that the risk of infection in a newborn from infected mothers is about 50% and can cause
bronchitis, pneumonia and neonatal conjunctivitis [14].
The antimicrobial treatment for pregnant patients with C. trachomatis infection is Erythro-
mycin or Azithromycin. The 1980s implementation of antenatal screening and treatment for
chlamydial infection in the USA significantly lowered the incidence of both neonatal chlamyd-
ial pneumonia and conjunctivitis, which was previously the most common cause of neonatal
conjunctivitis there [15]
Currently, there are no programs routinely conducted for C. trachomatis screening in ante-
natal care in Latin America, and there are no WHO recommendations for C. trachomatis
screening and treatment in pregnant women [16]. In addition, in Córdoba, Argentina, there is
little knowledge about the prevalence of C. trachomatis in women in their third trimester of
pregnancy. Taking into account data mentioned above, in this work we evaluated C. trachoma-
tis prevalence and genotypes present in Cordovan pregnant women with different age and
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socioeconomic status. Our results demonstrated that younger and low income pregnant
women are most affected.
Methods
Study design
We conducted a prospective study with patients from two Health Centers in Córdoba, Argen-
tina: Medical Specialties of Córdoba Municipality (MSCM) and a private laboratory from Cor-
doba city named LACE (LACE). Both MSCM participants (n = 301) and LACE participants
(n = 208) were recruited between September 2014 and February 2015. Women� 14 years
old having 35 weeks of gestation and interested in participate were enrolled after providing
informed consent approved by the Ethics Committee (C.I.E.S. Oulton- Romagosa. Date of
approval: 03/12/2014. Reference number: 014). It is important to emphasize that the Ethics
Committee approved the lack of parent or guardian consent in patients under 18 years,
according to the law 26,742 (Rights of the Patient in its relationship with Professionals and
Health Institutions). Health care professionals collected demographic data and swabs samples
from each patient. It should be noted that none of the patients enrolled in this study had com-
patible symptoms with C. trachomatis infection.
Clinical Samples: Five hundred and nine cervical swabs were collected from pregnant
women. All samples were placed in sterile tubes containing 1 ml of SPG (sucrose, phosphate,
glutamic acid), and subsequently sent to the Instituto de Virologı́a, Facultad de Ciencias Médi-
cas, Universidad Nacional de Córdoba, Argentina to be processed.
DNA Extraction: Two hundred μl of each sample were subjected to DNA extraction using
the Accuprep Genomic DNA Extraction Kit (BIONEER, Alameda, CA, USA) according to the
manufacturer’s instructions.
OmpA gene PCR: PCR DNA extract (5 μl) was used to amplify a 1087 pb fragment of the
ompA gene of C. trachomatis, using primers NRO (5’CTCAACTGTAACTGCGTATTT3’) and
NLO (5’ATGAAAAAACTCTTGAAATCG3´). PCR amplification processes commenced with a
4-minute denaturation step at 95˚C and continued with 49 amplification cycles. Each cycle
consisted of a first denaturation step at 95˚C for 1 min, an annealing step at 55˚C for 1 min
and a final step of chain elongation at 72˚ C for 1.5 min [17].
Cryptic Plasmid PCR: The primers used to generate a 201-bp fragment from the
cryptic plasmid of C. trachomatis were CTP1 (5'-TAGTAACTGCCAClTCATCA-3') and
CTP2 (5'-TTCCCCTTGTAATTCGTTGC-3'). The PCR amplification consisted of DNA
denaturation at 95˚C for 4 min followed by 35 cycles of amplification. Each cycle consisted
of 1 min at 95˚C, 1 min at 55˚C and 1.5 min at 72˚C followed by a final elongation at 72˚C
for 4 min. The ompA gene and cryptic plasmid PCR products were visualized after electro-
phoresis in a 1% agarose gel by ECO-Gel 20.000X Highway staining [17]. Positive and nega-
tive controls were used in all determinations of PCR (dx.doi.org/10.17504/protocols.io.
zeef3be).
Sequencing of the ompA gene: For sequence analysis, the PCR products were purified with
the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, US) and subjected to direct nucleo-
tide sequencing reaction in both directions using an ABI automatic sequencer. The sequences
were analyzed using the Molecular Evolutionary Genetics Analysis software package, MEGA
6 [18]. Sequences of the ompA derived from strains used in this study were analyzed along
with the next sequences from strains available in GenBank: VR-348-E (accession number
JX559522.1), VR-346-F (JX564244.1), VR-885-D (JX559520.1), VR-1477-C (559519.1),
VR-573-B (JX559518.1), VR-347-Ba (KP120856.1), VR-878-G (JX564245.1), VR-879-H
(JX564246.1), VR-880-I (JX564247.1), VR-886-J(JX648604.1), VR-887-K (JX564248.1),
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VR-901B-L1 (JX569832.1), VR-577-L2 (JX569836.1), VR-903-L3 (JX569834.1), China-F
(EU339316), Tailandia-F (KM369937), Rusia-F (KU963178), Holanda-F (AF265240), Austra-
lia-F (AY464145), Brasil-F (DQ442881), USA-F (CP006674), Dinamarca-F (AM901152),
Japon-F (AB915586), Argentina-D (EU191085), India-D (KP015822), USA-D (CP00677),
Francia-D (X62919), Japon-D (AB915583), Dinamarca-D(AM901213), Australia-D
(AY464176), Brasil-D (DQ442877), Islandia-D (AF414950), Suiza-L2 (DQ217607), Portugal-
L2 (EU296834), Holanda-L2 (AY586530), USA-L2 (CP002682), Japon-L2 (AB915593), Japon-
E (AB915585), Rusia-E (KU963184), Argentina-E (KC120818), Dinamarca-E (AM901208),
Tailandia-E (KM369935), Australia-E (AY464144), Francia-E (JN192145), India-E
(KP015823), Grecia-E (HQ637270), Brasil-E (FJ418802), Argentina-E (DQ890028), Holanda-
E (AF265237), USA-E (CP006675), USA-B (DQ064297), Italia-B (U80075), Australia-B
(AY464143), UK-B (M33636), Argentina-G (KC120822), Argentina-G (KC120825), India-G
(KP015825), Australia-G (AY464159), USA-G (DQ064299), Japon-G (AB915587), Dina-
marca-G (AM901157), India-Ia (KP015824), Japon-Ia (AB915589), USA-Ia (AF063201), Por-
tugal-Ia (DQ116398), USA-Ia (DQ064291), Argentina-Ia (EU000492), and the tree was rooted
with the ompA sequence of the Chlamydia suis (C. suis) strain (accession number AY687631).
Phylogenetic tree was constructed using the neighbor-joining method. Branching pattern con-
fidence levels were estimated by the bootstrap resampling of the data based on 1000 random
replicates.
Statistical Analysis: A descriptive analysis of the sociodemographic characteristics of the
patients was carried out. The results of the diagnostic tests were also analyzed. The normal dis-
tribution of the variables were expressed by the average and standard deviation and catego-
rized. The prevalence of C. trachomatis infection was calculated with their respective 95% CI.
Possible risk factors were evaluated using bivariate and multivariate logistic regression analy-
sis. Values of p<0.05 were considered significant. The analysis was performed with Epi info
software [19].
Results
We studied patients from 14 to 43 years of age with a median of 25 years. From 509 samples
analyzed in the present work, 35 were positive for C. trachomatis DNA, revealing a total preva-
lence of 6.9% in the pregnant population included in our study.
Thirty two samples were from patients with Low Economic Resources (LER) while the 3
remaining had Better Economic Resources (BER), revealing a very increased positivity in
the first patients mentioned (p 0,0001). In order to establish the LER, the patients had to be
under a Program called Universal Assignment per child. It is an economic aid provided by the
Argentine State to people with very low resources. Prevalence studies showed that positive
samples belong mainly to young women. The positive samples were distributed in different
age groups as can be seen in Table 1. Combining the age groups, we observed a significantly
increased rate of 11.6% (30/258) in women under 25 years, compared with 2% (5/251) in
patients over that age (p = 0,00003). It is interesting to note that pregnant patients between 21
and 25 years old have 2,9 more risk of suffering C. trachomatis infection than the rest of them
(OR: 2,9. CI: 1,4–5,8. p = 0,001) (Table 1).
Using OmpA sequencing C. trachomatis samples showed 7 different genotypes (B, D, E, F,
G, Ia and L2, Fig 1) of which genotype E was the most prevalent, as can be seen in Fig 1.
When a phylogenetic analysis was performed in sequenced samples three constructed with
three major subdivisions could be detected. Main branches do not match the patterns of tissue
tropisms and associated clinical presentation C. trachomatis infection in human hosts. (Fig 2).
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The frequencies, percentages OR (IC) and p of the demographic characteristics of all pregnant women admitted to the study are shown.
https://doi.org/10.1371/journal.pone.0217245.t001
Fig 1. Genotype distribution. The distribution of C. trachomatis genotypes found in pregnant women is shown.
https://doi.org/10.1371/journal.pone.0217245.g001
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Fig 2. Phylogenetic tree of the OmpA gene of C. trachomatis. The neighbor-joining method was used in MEGA& to
generate phylogenetic trees for ompA from DNA sequences (596bp). Initial nucleotide alignments generated with
strains that belong to this study are initiated by CO.
https://doi.org/10.1371/journal.pone.0217245.g002
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Discussion
In our knowledge this is the first report of C. trachomatis prevalence in women in their third
trimester of pregnancy from Cordoba, Argentina. According to published studies, the preva-
lence of this bacterium differs greatly around the world, with values between 0.1% and 25.7%
depending on the particular characteristics of the pregnant population and the methodology
used in the study [20, 21]. In Latin America, there are a few studies regarding C. trachomatis
prevalence in pregnant women and values reported are 5.9%, 10% and 11% for pregnant
women from Chile, Peru and Brazil respectively [22, 12, 23]. In the present study we found a
prevalence of 6.9%, which is within the range expected for the region. Highest percentages of
positivity were found in women between 21 to 25 years and with limited financial resources.
Young women are a vulnerable group of the population with regard to sexually transmitted
diseases. This is thought to be because of the relative immaturity of the genital tract, making it
prone to both trauma and infection, particularly in the developing transformation zone of the
cervix [6–7].
One of the limitations of this study is that there is an inevitable selection bias due to the
object of study, since women older than 25 years infected with C. trachomatis, might not have
entered it because the complications of this infection did not allow their pregnancy.
The prevalence of 6.9% detected in pregnant women in our study is lower than that
reported in asymptomatic young woman in Cordoba city, in which a prevalence of 8.9% was
observed [24], and it is greater than that found by Zucotti et al. in pregnant patients in the first
trimester who are seen in a private center where patients must pay for each medical practice
they need [25].
This might be due to the fact that the population studied by Zucotti has a good economic
level, which is why, according to our results; it is a protective factor for C. trachomatis infection.
As can be seen in Table 1, patients with LER have 8 times more risk of having C. trachoma-
tis infection than patients with BER (OR: 8.6 CI: 2.6–28.5); the opposite happens with patients
with BER since, according to statistics, this characteristic is protective for the aforementioned
infection (OR: 0.1 CI: 0.03–0.3).
There are mechanisms that can explain the association of C. trachomatis infection with low
socioeconomic status; these include a lower commitment to the control activities of STI, for
example, not attending the instances of diagnosis of them. In addition, there would be individ-
ual, family and community factors that would negatively impact on safe sexual practices, such
as the use of condoms [26].
The majority of published data clearly show that genotypes E and D are the most frequently
isolated from genital tract infections [27]. Most traditional genotypes in patients with urogeni-
tal infection would be E, F, D, G and K, constituting between 60 and 80% of positive patients
[28]. In our study genotypes E and F were the most frequently found in sequenced samples
from pregnant women, followed by genotypes D, L2, G, B and Ia. Sexually active, asymptom-
atic patients from Córdoba, Argentina also showed genotype E as the most frequently detected,
followed by genotype D and less frequently genotypes F and G [29]. In addition, genotypes E
and D were the most frequently isolated in a study conducted in Buenos Aires, Argentina in
adults and neonates with ophthalmia neonatarum [30].
In general, our results are consistent with those reported in most published studies, both in
Argentina [29, 30] and elsewhere in the world, which detects a higher prevalence of genotype
E, D and F in genital infections. However, our study reported also genotype L2, a finding not
usually reported in bibliography.
Regarding the phylogenetic analysis, the distribution of genotypes observed in our study
was similar to the distribution reported by Brunelle et al [31], which suggest that there is a
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marked trend in the group of serovars, which is not related to tissue tropism. Similar results
were obtained by Monetti et al and Lutter et al [17, 32], who also proposes that the MOMP var-
iability is due to antigenicity there of and immune selective pressure.
C. trachomatis infections are accompanied by psychosocial and economic complications.
For this reason, screening programs have been implemented in different countries. Their main
purpose is to reduce morbidity through early detection and appropriate specific treatment. As
a secondary objective of these programs is to decrease the overall prevalence of C. trachomatis
and subsequently reduce transmission in the population.
With regard to financial costs, it is considered that a screening program is effective when
the costs associated with the logistics of screening and treatment of positive cases is less than
or equal to the diagnosis and treatment of complications. Some publications show that screen-
ing programs put in place for this infection are profitable in selected populations [33–35].
With the data presented here, we would be able to state that low income pregnant women
less than 25 years would be one of the populations selected for C. trachomatis screening
programs.
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transmitted infections in pregnant women attending a public hospital in Chile. Rev. chil. infectol. 2012;
29 (5): 517–520.
23. Borborema-Alfaia AP, Freitas NS, Astolfi Filho S, Borborema-Santos CM. Braz J Infect Dis. 2013; 17
(5):545–550. https://doi.org/10.1016/j.bjid.2013.01.014 PMID: 23831212
24. Farinati A, Zitto T, Bottiglieri M, Gastaldello R, Cuffini C, Cannistraci R, et al. Infecciones asintomáticas
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